<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>BDX on Deep Analyst AI</title><link>https://deepanalyst.ai/tags/BDX/</link><description>Recent content in BDX on Deep Analyst AI</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><lastBuildDate>Mon, 09 Feb 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://deepanalyst.ai/tags/BDX/rss.xml" rel="self" type="application/rss+xml"/><item><title>The $1.75 Billion Amputation: Why Becton Dickinson Slashes Its Own Prognosis</title><link>https://deepanalyst.ai/posts/2026/02/bdx-1-75-billion-amputation-why-becton-dickinson-slashes-its-own-prognosis/</link><pubDate>Mon, 09 Feb 2026 00:00:00 +0000</pubDate><guid>https://deepanalyst.ai/posts/2026/02/bdx-1-75-billion-amputation-why-becton-dickinson-slashes-its-own-prognosis/</guid><description>The $1.75 Billion Amputation: Why Becton Dickinson Slashes Its Own Prognosis Wall Street loves a corporate diet plan, provided it doesn’t involve starving the shareholders. Becton, Dickinson and Company (BDX) just posted a Q1 earnings &amp;ldquo;beat&amp;rdquo; that felt less like a victory lap and more like a stumble into an open sharps container. While the headline numbers look pristine—revenue ticked up to $5.07 billion—the real story is the revised FY26 outlook below Street expectations.</description></item></channel></rss>